keyword
MENU ▼
Read by QxMD icon Read
search

sitagliptin

keyword
https://www.readbyqxmd.com/read/29340105/long-term-effects-of-sitagliptin-in-patients-with-type-2-diabetes-mellitus-and-hypertension-results-from-the-prologue-study
#1
Ziliang Ye, Hui Li, Haili Lu, Qiang Su, Lang Li
Background: The effects of sitagliptin in patients with type 2 diabetes mellitus and hypertension are unclear. Therefore, we evaluated the long-term effects of sitagliptin in those patients. Methods: In the PROLOGUE study, 365 patients were diagnosed as type 2 diabetes mellitus and hypertension, and 189 patients in the sitagliptin group, 176 patients in the conventional group. Fasting blood glucose (FBG), HbA1c, systolic pressure (SP), diastolic pressure (DP), serum urea nitrogen (BUN) and serum creatinine (SCR) were measured at the beginning of the study and after 12 and 24 months of treatment...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29330813/characteristics-of-elderly-patients-initiating-sitagliptin-or-non-dpp-4-inhibitor-oral-antihyperglycemic-agents-analysis-of-a-cross-sectional-us-claims-database
#2
Tongtong Wang, Ann Marie McNeill, Yong Chen, Edward A O'Neill, Samuel S Engel
INTRODUCTION: Previous analyses concluded that patients initiating treatment with sitagliptin are older and have more comorbidities than patients initiating treatment with other oral antihyperglycemic agents (OAHAs). However, these studies focused on the general population or subjects ≤ 65 years of age. We sought to compare differences in baseline characteristics of elderly patients (≥ 65 years of age) with T2DM initiating sitagliptin vs. non-DPP-4 inhibitor (non-DPP-4i) OAHA in the MarketScan® Medicare Supplemental Database...
January 12, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29325553/sitagliptin-improved-glucose-assimilation-in-detriment-of-fatty-acid-utilization-in-experimental-type-ii-diabetes-role-of-glp-1-isoforms-in-glut4-receptor-trafficking
#3
E Ramírez, B Picatoste, A González-Bris, M Oteo, F Cruz, A Caro-Vadillo, J Egido, J Tuñón, M A Morcillo, Ó Lorenzo
BACKGROUND: The distribution of glucose and fatty-acid transporters in the heart is crucial for energy consecution and myocardial function. In this sense, the glucagon-like peptide-1 (GLP-1) enhancer, sitagliptin, improves glucose homeostasis but it could also trigger direct cardioprotective actions, including regulation of energy substrate utilization. METHODS: Type-II diabetic GK (Goto-Kakizaki), sitagliptin-treated GK (10 mg/kg/day) and wistar rats (n = 10, each) underwent echocardiographic evaluation, and positron emission tomography scanning for [18F]-2-fluoro-2-deoxy-D-glucose (18FDG)...
January 11, 2018: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29317328/investigation-of-in-vitro-genotoxic-effects-of-an-anti-diabetic-drug-sitagliptin
#4
Deniz Yuzbasioglu, Cemile Enguzel-Alperen, Fatma Unal
Sitagliptin is an active ingredient of antidiabetic drug used in the treatment of type 2 diabetes mellitus (T2DM). In this study, the genotoxic effects of sitagliptin were determined in human lymphocytes by using chromosome aberrations (CAs), sister chromatid exchanges (SCEs), micronucleus (MN) and comet assays. 31.25-1000 μg/mL concentrations of sitagliptin were used. Sitagliptin significantly increased the frequency of CAs and SCEs at the highest concentration at 24 h treatment and all concentrations (except 250 μg/mL for CA, except 31...
January 6, 2018: Food and Chemical Toxicology
https://www.readbyqxmd.com/read/29314506/efficacy-and-safety-of-sitagliptin-in-elderly-patients-with-type%C3%A2-2-diabetes-mellitus
#5
Motoko Tago, Jun-Ichi Oyama, Yoshiko Sakamoto, Aya Shiraki, Fumi Uchida, Atsuko Chihara, Hideo Ikeda, Shigetaka Kuroki, Shigeki Gondo, Taketo Iwamoto, Yasufumi Uchida, Koichi Node
AIM: The aim of the present study was to assess the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus. METHODS: A total of 188 patients were enrolled who had type 2 diabetes mellitus with poor glycemic profiles (hemoglobin A1c [HbA1c] ≥6.2%). Patients were assigned to one of three age groups (<65, 65-74 and ≥75 years) and received 50-100 mg of sitagliptin daily for 12 months. Changes in HbA1c classified by age and body mass index (BMI) were assessed in addition to physiological parameters...
January 4, 2018: Geriatrics & Gerontology International
https://www.readbyqxmd.com/read/29313282/ertugliflozin-and-sitagliptin-co-initiation-in-patients-with-type-2-diabetes-the-vertis-sita-randomized-study
#6
Sam Miller, Tania Krumins, Haojin Zhou, Susan Huyck, Jeremy Johnson, Gregory Golm, Steven G Terra, James P Mancuso, Samuel S Engel, Brett Lauring
INTRODUCTION: Ertugliflozin is an oral sodium-glucose cotransporter 2 inhibitor that is being developed to treat type 2 diabetes mellitus (T2DM). This study assessed the efficacy and safety of co-initiation of ertugliflozin and sitagliptin compared with placebo in patients with T2DM inadequately controlled on diet and exercise. METHODS: In this phase III, randomized, double-blind, multicenter, placebo-controlled 26-week study (NCT02226003), patients with T2DM and glycated hemoglobin (HbA1c) 8...
January 8, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29313267/impact-of-canagliflozin-treatment-on-health-related-quality-of-life-among-people-with-type-2-diabetes-mellitus-a-pooled-analysis-of-patient-reported-outcomes-from-randomized-controlled-trials
#7
Jennifer Cai, Linda M Delahanty, Sydney Akapame, April Slee, Shana Traina
BACKGROUND: Evidence from patient-reported outcomes in clinical trials may explain health-related behaviors observed in the real world. OBJECTIVE: The purpose of this analysis was to evaluate the effect of treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with placebo or sitagliptin on health-related quality-of-life outcomes in participants with type 2 diabetes mellitus from the clinical development program. METHODS: Patient-reported outcomes data from four randomized controlled trials of canagliflozin (n = 2536) were pooled and analyzed to evaluate participants' interest in continuing study medication; satisfaction with weight; and physical, mental, and emotional health after 26-52 weeks of treatment with canagliflozin vs...
January 8, 2018: Patient
https://www.readbyqxmd.com/read/29311155/increased-risk-of-severe-hypoglycemic-events-before-and-after-cardiovascular-outcomes-in-tecos-suggests-an-at-risk-type-2-diabetes-frail-patient-phenotype
#8
Eberhard Standl, Susanna R Stevens, Paul W Armstrong, John B Buse, Juliana C N Chan, Jennifer B Green, John M Lachin, Andre Scheen, Florence Travert, Frans Van de Werf, Eric D Peterson, Rury R Holman
OBJECTIVE: Severe hypoglycemic events (SHEs) in type 2 diabetes are associated with subsequent cardiovascular (CV) event risk. We examined whether CV events were associated with subsequent SHE risk. RESEARCH DESIGN AND METHODS: Time-dependent associations between SHEs and a composite CV end point (fatal/nonfatal myocardial infarction or stroke, hospitalization for unstable angina, hospitalization for heart failure [hHF]) were examined post hoc in 14,671 TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) participants with type 2 diabetes and CV disease followed for a median of 3...
January 8, 2018: Diabetes Care
https://www.readbyqxmd.com/read/29299152/high-dose-sitagliptin-for-systemic-inhibition-of-dipeptidylpeptidase-4-to-enhance-engraftment-of-single-cord-umbilical-cord-blood-transplantation
#9
Sherif S Farag, Robert Nelson, Mitchell S Cairo, Heather A O'Leary, Shuhong Zhang, Carol Huntley, David Delgado, Jennifer Schwartz, Mohammad Abu Zaid, Rafat Abonour, Michael Robertson, Hal Broxmeyer
Delayed engraftment remains a limitation of umbilical cord blood (UCB) transplantation. We previously showed that inhibition of dipeptidylpeptidase (DPP)-4 using sitagliptin 600 mg daily was safe with encouraging results on engraftment, but inhibition was not sustained. We evaluated the efficacy and feasibility of higher doses of sitagliptin to enhance engraftment of UCB in patients with hematological cancers. Fifteen patients, median age 41 (range, 18-59) years, received single UCB grafts matched at 4 (n=11) or 5 (n=4) of 6 HLA loci with median nucleated cell dose of 3...
December 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/29285488/comparative-effectiveness-and-safety-of-empagliflozin-on-cardiovascular-mortality-and-morbidity-in-adults-with-type-2-diabetes
#10
Wilbert S Aronow, Tatyana A Shamliyan
Background: Based on a single placebo-controlled randomized clinical trial, empagliflozin is licensed to reduce cardiovascular death in diabetes and comorbid cardiovascular disease. Methods: We examined the comparative effectiveness of empagliflozin on mortality and cardiovascular morbidity in type 2 diabetes. We conducted random-effects direct frequentist meta-analyses of aggregate data and appraised the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology...
December 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29275488/the-renoprotective-effect-and-safety-of-a-dpp-4-inhibitor-sitagliptin-at-a-small-dose-in-type-2-diabetic-patients-with-a-renal-dysfunction-when-changed-from-other-dpp-4-inhibitors-real-trial
#11
Koichi Kanozawa, Yuichi Noguchi, Souichi Sugahara, Satoko Nakamura, Hirohisa Yamamoto, Keiko Kaneko, Rika Kono, Saeko Sato, Tomonari Ogawa, Hajime Hasegawa, Shigehiro Katayama
BACKGROUND: We conducted the multicenter, prospective, open-label study in type 2 diabetic (T2DM) patients with renal dysfunction, to clarify the efficacy and the safety in relation to renal function and glycemic control, and the economic effect when other dipeptidyl peptidase-4 (DPP-4) inhibitors were switched to a small dose of sitagliptin depending on their renal function. METHODS: Vildagliptin, alogliptin, or linagliptin received for more than 2 months were changed to sitagliptin at 25 or 12...
December 23, 2017: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/29258504/dipeptidyl-peptidase-4-inhibitor-decreases-the-risk-of-atrial-fibrillation-in-patients-with-type-2-diabetes-a-nationwide-cohort-study-in-taiwan
#12
Chia-Yu Chang, Yung-Hsin Yeh, Yi-Hsin Chan, Jia-Rou Liu, Shang-Hung Chang, Hsin-Fu Lee, Lung-Sheng Wu, Kun-Chi Yen, Chi-Tai Kuo, Lai-Chu See
BACKGROUND: Whether dipeptidyl peptidase-4 inhibitor (DPP4i) is associated with a lower risk of new-onset atrial fibrillation (AF) in patients with diabetes remains unclear. This study aimed to evaluate the risk of AF associated with use of DPP4i among a longitudinal cohort of patients with diabetes. METHODS: Over a 3-year period, 480,000 patients with diabetes were analyzed utilizing Taiwan's National Health Insurance Research Database and 90,880 patients taking metformin as first-line therapy were enrolled...
December 19, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29241903/effect-of-dipeptidyl-peptidase-4-inhibitors-on-heart-failure-a-network-meta-analysis
#13
COMPARATIVE STUDY
Wen-Qin Guo, Lang Li, Qiang Su, Wei-Ran Dai, Zi-Liang Ye
BACKGROUND: Previous meta-analyses evaluating the effectiveness of individual dipeptidyl peptidase-4 (DPP-4) inhibitors on the risk of heart failure (HF) were limited because of the small number of trials with direct comparisons between two treatments. METHODS: A Bayesian network meta-analysis was performed to investigate the relationship between DPP-4 inhibitors and the risk of HF in patients with type-2 diabetes mellitus. The primary outcome was the occurrence of HF or hospital admission for HF...
December 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29239764/treatment-choices-for-the-glycaemic-management-of-patients-with-type-2-diabetes-and-chronic-kidney-disease-analysis-of-the-sail-patient-linked-dataset
#14
Thinzar Min, Gareth I Davies, Sam Rice, James Chess, Jeffrey W Stephens
AIMS: Chronic kidney disease (CKD) is common in type 2 diabetes and limits the treatment choices for glycaemic control. Our aim was to examine real-world prescribing for managing hyperglycaemia in the presence of CKD. METHODS: The SAIL (Secure Anonymised Information Linkage) databank was used to examine prescribing during the period from the 1st of January to 30th December 2014. CKD was defined as:- none or mild CKD, eGFR ≥60mL/min/1.73m2; moderate CKD eGFR <60mL/min/1...
November 23, 2017: Diabetes & Metabolic Syndrome
https://www.readbyqxmd.com/read/29238432/renal-function-during-an-open-label-prospective-observational-trial-of-sitagliptin-in-patients-with-diabetes-a-sub-analysis-of-the-jamp-study
#15
Osamu Tomonaga, Hiroshi Sakura, Naotake Hashimoto, Kazuo Sasamoto, Hiroshi Ohashi, Sumiko Hasumi, Noriko Ujihara, Tadasu Kasahara, Hideo Nunome, Masashi Honda, Yasuhiko Iwamoto
Background: The aim of the study was to determine the effects of sitagliptin on renal function in a diabetic population including patients with normal renal function. Methods: We analyzed the association between 12-month, 50 mg/day sitagliptin and renal function in outpatients with type 2 diabetes mellitus and poor blood glucose control in a subset of patients in the larger Januvia Multicenter Prospective Trial in Type 2 Diabetes observational study. Stratified analyses of changes in estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR) were performed...
January 2018: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/29236222/an-indirect-comparison-of-changes-in-the-impact-of-weight-on-quality-of-life-among-subjects-with-type-2-diabetes-treated-with-antihyperglycemic-agents-in-dual-therapy-with-metformin
#16
Shana B Traina, April Slee, Suzy Van Sanden, Joris Diels
INTRODUCTION: It is important to capture the patient experience with a diabetes treatment in clinical trials; however, use of instruments to assess patient-reported outcomes (PROs) in diabetes trials is inconsistent and results may not be reported alongside primary efficacy data. In lieu of head-to-head data, indirect comparisons can be used to compare competing interventions. In this study, we used indirect comparison methods to assess differences in PRO score changes between canagliflozin and other antihyperglycemic agents as add-on to metformin...
December 13, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29231750/concordance-with-prescribing-information-dosage-recommendations-for-dipeptidyl-peptidase-4-inhibitors-among-type-2-diabetes-mellitus-patients-with-moderate-to-severe-chronic-kidney-disease
#17
Huan Huang, Sharash Shetty, Elise Bauer, Kathleen Lang
OBJECTIVE: To estimate the proportion of patients with moderate to severe chronic kidney disease (CKD) whose initial DPP4-i dosage was concordant with prescribing information (label) recommendations in the United States. METHODS: Adult patients with T2DM who initiated a DPP4-i (linagliptin, sitagliptin, saxagliptin) between Jan 1, 2011 and Jun 30, 2014 were identified using electronic medical records and administrative claims, with index date being the date of first observed DPP4-i treatment...
December 12, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29228568/sitagliptin-and-oral-cancer-risk-in-type-2-diabetes-patients
#18
Chin-Hsiao Tseng
The reimbursement database of the Taiwan's National Health Insurance was used to evaluate oral cancer risk after sitagliptin use. Patients newly diagnosed of type 2 diabetes during 1999-2008 were recruited. A 1:1 propensity score matched-pair sample of 39195 ever users and 39195 never users were followed up until December 31, 2011. Cox regression incorporated with the inverse probability of treatment weighting using propensity score was used to estimate hazard ratios. Results showed that the overall hazard ratio was not statistically significant (0...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29227575/effect-of-a-single-dose-of-the-dpp-4-inhibitor-sitagliptin-on-%C3%AE-cell-function-and-incretin-hormone-secretion-after-meal-ingestion-in-healthy-volunteers-and-drug-na%C3%A3-ve-well-controlled-type-2-diabetes-subjects
#19
Wathik Alsalim, Olga Göransson, Richard D Carr, Roberto Bizzotto, Andrea Tura, Giovanni Pacini, Andrea Mari, Bo Ahrén
To explore the effects of a single dose of the DPP-4 inhibitor sitagliptin on glucose-standardized insulin secretion and β-cell glucose sensitivity after meal ingestion, twelve healthy- and twelve drug naïve well-controlled type 2 diabetes subjects (T2D; mean HbA1c 43 mmol/mol, 6.2%) received sitagliptin (100mg) or placebo before a meal (525 kcal). β-cell function was measured as the insulin secretory rate at a standardized glucose concentration and the β-cell glucose sensitivity (the slope between glucose and insulin secretory rate)...
December 11, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29226729/formulation-of-sitagliptin-loaded-oral-polymeric-nano-scaffold-process-parameters-evaluation-and-enhanced-anti-diabetic-performance
#20
Mohammed Asadullah Jahangir, Ruqaiyah Khan, Syed Sarim Imam
PURPOSE: The aim of the study to formulate and statistically optimize sitagliptin-loaded eudragit nanoparticles (SIT-NPs) and evaluate the in-vitro pharmaceutical quality and in-vivo anti-diabetic assessment. METHOD: SIT-NPs were prepared by using combination method of solvent evaporation and nano-precipitation techniques. The influence of different independent variables as eudragit RL100 concentration (%), tween 80 concentration (%) and sonication time (min) were evaluated on dependent variables like particle size (nm), drug loading (%) and in-vitro drug release (%)...
December 9, 2017: Artificial Cells, Nanomedicine, and Biotechnology
keyword
keyword
28643
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"